<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">20665499</PMID>
        <DateCompleted>
            <Year>2010</Year>
            <Month>12</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0008-543X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>116</Volume>
                    <Issue>21</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Nov</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer</Title>
                <ISOAbbreviation>Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial.</ArticleTitle>
            <Pagination>
                <MedlinePgn>4973-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.25498</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The treatment of patients with advanced or recurrent endometrial cancer remains problematic, because chemotherapy and hormonal therapy have yielded low response rates and limited progression-free survival. Because the combination of gemcitabine and cisplatin demonstrated synergism in preclinical studies, the authors attempted to determine the efficacy and toxicity of this combination in women with advanced or recurrent endometrial cancer.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A prospective, single-institution, phase 2 study was performed in women with histologically documented International Federation of Gynecology and Obstetrics (FIGO) stage III or IV or recurrent endometrioid endometrial carcinoma. Gemcitabine at a dose of 1000 mg/m2 and cisplatin at a dose of 35 mg/m2 were administered intravenously on Days 1 and 8 of each 21-day cycle; because of myelosuppression, the protocol was revised to gemcitabine at a dose of 900 mg/m2 and cisplatin at a dose of 30 mg/m2. Patients were treated until disease progression, unacceptable toxicity, or complete response.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 21 patients were enrolled and received a median of 5 courses of therapy (range, 1-9 courses). The median age at the time of study enrollment was 62 years (range, 41-75 years). Of 20 evaluable patients, 2 (10%) had a confirmed complete response, 8 (40%) had a partial response, 6 (30%) had stable disease, and 4 (20%) developed progressive disease. The median progression-free survival was 7.5 months (range, 2.3-33.6 months), and the median overall survival was 18.2 months (range, 2.5-49.4 months). The development of toxicity mandated dose reductions in 16 of 20 patients (80%). Eighteen patients experienced grade 3 or 4 toxic effects (graded according to the Common Terminology Criteria for Adverse Events [version 3.0]).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The objective response rate of 50% noted with gemcitabine and cisplatin combination chemotherapy merits the further development of this regimen in women with advanced or recurrent endometrial cancer.</AbstractText>
                <CopyrightInformation>Copyright Â© 2010 American Cancer Society.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Brown</LastName>
                    <ForeName>Jubilee</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. jbbrown@mdanderson.org</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smith</LastName>
                    <ForeName>Judith A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramondetta</LastName>
                    <ForeName>Lois M</ForeName>
                    <Initials>LM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sood</LastName>
                    <ForeName>Anil K</ForeName>
                    <Initials>AK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramirez</LastName>
                    <ForeName>Pedro T</ForeName>
                    <Initials>PT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Coleman</LastName>
                    <ForeName>Robert L</ForeName>
                    <Initials>RL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Levenback</LastName>
                    <ForeName>Charles F</ForeName>
                    <Initials>CF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Munsell</LastName>
                    <ForeName>Mark F</ForeName>
                    <Initials>MF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jung</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wolf</LastName>
                    <ForeName>Judith K</ForeName>
                    <Initials>JK</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 CA016672</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer</MedlineTA>
            <NlmUniqueID>0374236</NlmUniqueID>
            <ISSNLinking>0008-543X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0W860991D6</RegistryNumber>
                <NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>B76N6SBZ8R</RegistryNumber>
                <NameOfSubstance UI="C056507">gemcitabine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q20Q21Q62J</RegistryNumber>
                <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Cancer. 2011 Aug 1;117(15):3529; author reply 3529-30</RefSource>
                <PMID Version="1">21287533</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003841" MajorTopicYN="N">Deoxycytidine</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016889" MajorTopicYN="N">Endometrial Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>7</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>7</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20665499</ArticleId>
            <ArticleId IdType="doi">10.1002/cncr.25498</ArticleId>
            <ArticleId IdType="pmc">PMC4210375</ArticleId>
            <ArticleId IdType="mid">NIHMS628366</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 1999 Jan;17(1):12-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10458212</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 1999 Jun;80(7):981-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10362105</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2006 Jan 1;24(1):36-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16330675</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2006 Oct 10;24(29):4699-707</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16966687</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 2006 Nov;103(2):518-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16690105</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 2007 Mar;104(3):580-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17052747</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Thorac Oncol. 2006 Jan;1(1):19-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17409822</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Clin Oncol. 2008 Feb;13(1):62-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18307021</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Gynecol Cancer. 2008 Jul-Aug;18(4):803-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17944917</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Breast Cancer. 2008 Oct;8(5):432-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18952557</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19474385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 2009 Dec;115(3):443-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19804902</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 1999 Sep;74(3):432-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10479505</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 2000 Jan;76(1):63-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10620443</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2000 Mar;6(3):773-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10741696</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2001 Apr;12(4):541-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11398890</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2002 Jul;13(7):1080-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12176787</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anticancer Drugs. 2002 Sep;13(8):839-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12394269</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 2002 Dec;87(3):247-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12468321</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Pharmacol. 2003 Jan 15;65(2):275-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12504803</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 2003 Jan;88(1):17-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12504621</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 2003 Jan;88(1):35-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12504624</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2003 Mar;14(3):441-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12598351</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Pharmacol. 2003 Apr;63(4):862-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12644587</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 2003 Mar;88(3):277-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12648575</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Clin Oncol. 2003 Apr;26(2):174-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12714891</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2003 Jun 1;21(11):2110-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12775736</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 2004 Jan;92(1):314-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14751176</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2004 Jun 1;22(11):2159-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15169803</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2004 Oct 1;22(19):3902-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15459211</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Treat Rep. 1978 Jan;62(1):159-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">626996</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Clin Oncol. 1984 Jun;7(3):253-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6539565</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 1989 Apr;33(1):68-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2703169</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 1991 Mar;40(3):264-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2013451</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 1993 Dec;51(3):397-400</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8112651</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Gynaecol Oncol. 1994;15(4):263-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7957332</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst Monogr. 1995;(19):13-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7577198</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 1996 Mar;2(3):521-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9816199</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
